Stage III Breast Cancer Recruiting Phase 2 Trials for Sargramostim (DB00020)

IndicationStatusPhase
DBCOND0031775 (Stage III Breast Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03012100Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast CancerTreatment